000143291 001__ 143291
000143291 005__ 20240229112547.0
000143291 0247_ $$2doi$$a10.1093/neuonc/noz058
000143291 0247_ $$2pmid$$apmid:30923826
000143291 0247_ $$2ISSN$$a1522-8517
000143291 0247_ $$2ISSN$$a1523-5866
000143291 0247_ $$2altmetric$$aaltmetric:58010525
000143291 037__ $$aDKFZ-2019-00889
000143291 041__ $$aeng
000143291 082__ $$a610
000143291 1001_ $$0P:(DE-He78)a8c698e0904394407c5261932915daa5$$aHübner, Jens-Martin$$b0$$eFirst author$$udkfz
000143291 245__ $$aEZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
000143291 260__ $$aOxford$$bOxford Univ. Press$$c2019
000143291 3367_ $$2DRIVER$$aarticle
000143291 3367_ $$2DataCite$$aOutput Types/Journal article
000143291 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1569243486_17585
000143291 3367_ $$2BibTeX$$aARTICLE
000143291 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143291 3367_ $$00$$2EndNote$$aJournal Article
000143291 520__ $$aPosterior fossa A (PFA) ependymomas comprise one out of nine molecular groups of ependymoma. PFA tumors are mainly diagnosed in infants and young children, show a poor prognosis and are characterized by a lack of the repressive histone H3 lysine 27 trimethylation (H3K27me3) mark. Recently, we reported CXorf67 overexpression as hallmark of PFA ependymoma and showed that CXorf67 can interact with EZH2 thereby inhibiting polycomb repressive complex 2 (PRC2), but the mechanism of action remained unclear.We performed mass spectrometry (MS) and peptide modelling analyses to identify the functional domain of CXorf67 responsible for binding and inhibition of EZH2. Our findings were validated by immunocytochemistry, western blot and methyltransferase assays.We find that the inhibitory mechanism of CXorf67 is similar as in diffuse midline gliomas harboring H3K27M mutations. A small, highly conserved peptide sequence located in the C-terminal region of CXorf67 mimics the sequence of K27M mutated histones and binds to the SET domain of EZH2. This interaction blocks EZH2 methyltransferase activity and inhibits PRC2 function causing de-repression of PRC2 target genes including genes involved in neurodevelopment.Expression of CXorf67 is an oncogenic mechanism that drives H3K27 hypomethylation in PFA tumors by mimicking K27M mutated histones. Disrupting the interaction between CXorf67 and EZH2 may serve as a novel targeted therapy for PFA tumors but also for other tumors that overexpress CXorf67. Based on its function, we have renamed CXorf67 into EZH Inhibitory Protein (EZHIP).
000143291 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143291 588__ $$aDataset connected to CrossRef, PubMed,
000143291 7001_ $$0P:(DE-HGF)0$$aMüller, Torsten$$b1
000143291 7001_ $$0P:(DE-HGF)0$$aPapageorgiou, Dimitris N$$b2
000143291 7001_ $$0P:(DE-He78)c865b84c0142dfa1def7dfeb70302918$$aMauermann, Monika$$b3$$udkfz
000143291 7001_ $$0P:(DE-He78)939d5891259c638c1ab053b1456a578c$$aKrijgsveld, Jeroen$$b4$$udkfz
000143291 7001_ $$aRussell, Robert B$$b5
000143291 7001_ $$aEllison, David W$$b6
000143291 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b7$$udkfz
000143291 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b8$$udkfz
000143291 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b9$$eLast author$$udkfz
000143291 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noz058$$n7$$p878-889$$tNeuro-Oncology$$v21$$x1523-5866$$y2019
000143291 909CO $$ooai:inrepo02.dkfz.de:143291$$pVDB
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8c698e0904394407c5261932915daa5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c865b84c0142dfa1def7dfeb70302918$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)939d5891259c638c1ab053b1456a578c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143291 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143291 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143291 9141_ $$y2019
000143291 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143291 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000143291 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143291 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143291 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143291 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143291 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143291 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143291 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143291 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143291 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000143291 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000143291 9201_ $$0I:(DE-He78)B230-20160331$$kB230$$lProteomik$$x1
000143291 980__ $$ajournal
000143291 980__ $$aVDB
000143291 980__ $$aI:(DE-He78)B062-20160331
000143291 980__ $$aI:(DE-He78)B230-20160331
000143291 980__ $$aUNRESTRICTED